Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Guidant

This article was originally published in The Gray Sheet

Executive Summary

Firm announces Oct. 6 it has launched its MultiLink Vision RX coronary stent system in Japan. Guidant's cobalt chromium stent technology will be the platform for its XIENCE V everolimus-eluting system, which is being compared with Boston Scientific's Taxus Express 2 paclitaxel-eluting stent in the SPIRIT II and III trials (1"The Gray Sheet" Sept. 26, 2005, In Brief)...

You may also be interested in...



Guidant SPIRIT in Japan

Guidant announces Dec. 13 the launch of an 88-patient registry in Japan as part of the SPIRIT III trial of its Xience V everolimus-eluting stent. SPIRIT III is part of the Harmonization By Doing initiative to promote regulatory convergence between the U.S. and Japan, which allows Guidant to conduct one trial for both countries. Guidant hopes it will lead to earlier introduction of the stent in Japan. The company also announces it has passed the halfway enrollment mark in the SPIRIT III U.S. arm, a 1,002-patient, prospective, randomized, single-blind trial comparing Xience V to Boston Scientific's Taxus Express 2 paclitaxel-eluting stent (1"The Gray Sheet" Oct. 10, 2005, In Brief)...

Guidant’s SPIRIT

Over 300 patients are enrolled in the SPIRIT II and SPIRIT III European drug-eluting stent clinical trials, triggering a $60 mil. milestone payment to drug-supplier Novartis, Guidant announces Sept. 21. The trial compares Guidant's Xience V everolimus-eluting stent to Boston Scientific's Taxus paclitaxel-eluting stent. In June, FDA approved an expansion of the SPIRIT III trial to include 1,292 patients at up to 80 sites (1"The Gray Sheet" Aug. 29, 2005, In Brief). The notified body that will review Xience for CE Mark completed its inspection of the firm's Temecula, Calif. facility...

Butterfly Network’s CEO Sees Blank Check Deal As Path To ‘Democratize’ Portable Imaging Platform

Butterfly Network chose SPAC route with Longview Acquisition Corp. to scale its business and expand into the home market in 2021.

UsernamePublicRestriction

Register

OM004559

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel